Research into the molecular causes and mechanisms of disease has a high potential for innovation and value creation. We are breaking new ground in order to make the findings of basic medical research and clinical care available for the recovery of our patients and the benefit of our society. This allows us to develop therapeutic and diagnostic concepts with high efficiency and quality to the biotechnological prototype stage, which marks the professional interface at the transition from academic to post-academic space. Our inaugural success in establishing and exiting a biotech start-up, InoCard GmbH, in 2014 and 2017, respectively, exemplifies this commitment. The expertise garnered through these endeavors serves as a solid foundation for future professionally designed ventures, such as AaviGen GmbH (https://aavigen.com), which consistently advances the therapeutic and diagnostic concepts of InoCard. Our mission is to provide personalized precision medicine for cardiovascular and cardiopulmonary diseases. We achieve this by combining the strengths of the academic and bioindustrial (post-academic) sectors and challenging traditional thought patterns. A current focus is on the use of nucleic acid- and peptide-based therapeutics, which can be targeted to the heart muscle by organ-specific adeno-associated viruses (AAV), among other things.Drawing from our experience as founders of InoCard and AaviGen in an academic environment, the development and management of uniQure Germany in Heidelberg as a model project, and as uniQure leadership team member in an international environment, we bring a unique blend of medical and scientific expertise, coupled with the economic acumen and experience of the biotech industry.With the previous financing rounds for AaviGen (https://aavigen.com), the strategic partnerships and our SAB, we have laid a solid foundation for the clinical transition of the next generation of precision gene therapies for genetic and acquired forms of heart failure. If you are interested, please visit our AaviGen linkedin account to find out about the latest developments as our start-up enters the next stage of growth.